How do you bridge the gap between prophylactic and therapeutic vaccines?
"A vaccine that ‘treats' a disease before it causes morbidity would bridge the gap between prophylactics and therapeutics."
But how?
Download this presentation to discover more about bridging the gap between prophylactic and therapeutic vaccines including:
· The next-best thing to prophylaxis
· Therapy of still-healthy patients requires validated biomarkers and a diagnostic-compliant target population
· Avoiding adjuvant IN vaccine formulations reduces adjuvant-specific regulatory risks
· ProCervix, first clinical-stage therapeutic vaccine to prevent disease progression in healthy HR-HPV-infected patients
Dr Benedikt Timmerman, Chief Executive Officer, Genticel
Download the presentation here >
To learn more about this and the other topics discussed at this the World Vaccine Congress Lyon 2012, please click here >
For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation